Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

To contribute published user compound and/or population files, upload your files here: Upload Model Files

Searching Tips

You can use a * character as a wildcard at the end of a alphanumeric search term. The search term must start with at least one character before the wildcard. E.g., Rifam* will get you “Rifampicin” and “Rifampin”.
You can also use a * character as a wildcard in the middle of a alphanumeric search term. The search term must still start with at least one character before the wildcard. E.g., Rif*in will also get you “Rifampicin” and “Rifampin” .
You can also use a * character as a wildcard at the start of a alphanumeric search term. However you must use forward slashes to delimit the search term and use a point before the wildcard. E.g., /.*picin/ will only get you “Rifampicin”.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Found 141 Matches

Emtricitabine PBPK Model Review 2020

Model Files Publication

Emtricitabine PBPK Model Review 2020

Search Score: 1

Primaquine

Model Files Publication

Brand Name(s) include: Jasoprim, Malirid, Neo-Quipenyl, Pimaquin, Pmq, Primachina, Primacin, Primaquina, Primaquine, Primaquine diphosphate, Primaquine Phosphate, and Remaquin

Disease: Malaria, Plasmodium vivax, Plasmodium ovale

Drug Class: Antimalarial

Related Files: Carboxyprimaquine (metabolite)

Date Updated: March 2022

The model at-a-glance

Absorption Model	First-Order
Volume of Distribution	Full PBPK (Method 2)
Routes of Elimination	89% MAO (entered using ‘user-UGT’ as a surrogate in the Simulator), 11% CYP2D6
Perpetrator DDI	CYP1A2 Inhibitor (in vitro)
Validation	6 studies with single (15 to 45 mg) and multiple (15 mg QD) dosing. 100% of Cmax and AUC values within 1.5-fold. No clinical DDI studies to verify contribution of metabolic routes
Limitations	The active metabolites of primaquine have not characterized due to their instability. Therefore, a PBPK model for active metabolites cannot be developed in their own right. Qualitative data suggests a role of P-gp, however, Jmax and Km values have not been measured. There is evidence of enantiomer specific metabolism for primaquine which has not been considered in the current model.
Updates in Version 19	Updated in vitroprotein and blood binding data and subsequent back calculation of CLint (retrograde approach) f_u: 0.19 -> 0.26 B:P: 1 -> 0.82 Converted from minimal PBPK model to full PBPK model

Search Score: 1

SouthAfrican_Population_V15R1_CPTR_20170308

Model Files Publication

Search Score: 1

Iloperidone_V12R2_USFDA_20160510

Model Files Publication

Note/correction: predicted B/P should be 0.70, predicted Fa should be 0.84

Search Score: 1

Search the PBPK Model Repository

Searching Tips

Emtricitabine PBPK Model Review 2020

Primaquine

The model at-a-glance

SouthAfrican_Population_V15R1_CPTR_20170308

Iloperidone_V12R2_USFDA_20160510

Your Privacy